Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.